Literature DB >> 31145100

Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.

Brian R Winters1, Navonil De Sarkar2,3, Sonali Arora3, Hamid Bolouri3, Sujata Jana3, Funda Vakar-Lopez4, Heather H Cheng2, Michael T Schweizer2, Evan Y Yu2, Petros Grivas2, John K Lee2,3, Lori Kollath1, Sarah K Holt1, Lisa McFerrin5, Gavin Ha5, Peter S Nelson2,3, Robert B Montgomery2, Jonathan L Wright1,5, Hung-Ming Lam1,6, Andrew C Hsieh2,3.   

Abstract

BACKGROUND: Little is known about the genomic differences between metastatic urothelial carcinoma (LTUC) and upper tract urothelial carcinoma (UTUC). We compare genomic features of primary and metastatic UTUC and LTUC tumors in a cohort of patients with end stage disease.
METHODS: We performed whole exome sequencing on matched primary and metastatic tumor samples (N=37) from 7 patients with metastatic UC collected via rapid autopsy. Inter- and intra-patient mutational burden, mutational signatures, predicted deleterious mutations, and somatic copy alterations (sCNV) were analyzed.
RESULTS: We investigated 3 patients with UTUC (3 primary samples, 13 metastases) and 4 patients with LTUC (4 primary samples, 17 metastases). We found that sSNV burden was higher in metastatic LTUC compared to UTUC. Moreover, the APOBEC mutational signature was pervasive in metastatic LTUC and less so in UTUC. Despite a lower overall sSNV burden, UTUC displayed greater inter- and intra-individual genomic distances at the copy number level between primary and metastatic tumors than LTUC. Our data also indicate that metastatic UTUC lesions can arise from small clonal populations present in the primary cancer. Importantly, putative druggable mutations were found across patients with the majority shared across all metastases within a patient.
CONCLUSIONS: Metastatic UTUC demonstrated a lower overall mutational burden but greater structural variability compared to LTUC. Our findings suggest that metastatic UTUC displays a greater spectrum of copy number divergence from LTUC. Importantly, we identified druggable lesions shared across metastatic samples, which demonstrate a level of targetable homogeneity within individual patients.

Entities:  

Keywords:  Cancer; Oncology; Urology

Year:  2019        PMID: 31145100      PMCID: PMC6629128          DOI: 10.1172/jci.insight.128728

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  65 in total

1.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

2.  A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Authors:  Atreya Dash; Joseph A Pettus; Harry W Herr; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Paul Russo; Mary G Boyle; Matthew I Milowsky; Dean F Bajorin
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

3.  Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.

Authors:  Kevin A David; Katherine Mallin; Matthew I Milowsky; Jamie Ritchey; Peter R Carroll; David M Nanus
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

4.  BEDTools: a flexible suite of utilities for comparing genomic features.

Authors:  Aaron R Quinlan; Ira M Hall
Journal:  Bioinformatics       Date:  2010-01-28       Impact factor: 6.937

5.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

6.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Authors:  Ben Langmead; Cole Trapnell; Mihai Pop; Steven L Salzberg
Journal:  Genome Biol       Date:  2009-03-04       Impact factor: 13.583

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  8 in total

1.  Two cases of osteoblastic bone metastasis from muscle-invasive bladder cancer with discrepancy in response to chemotherapy: problems and limitations of bone biopsy.

Authors:  Takuto Ogasawara; Toshiaki Tanaka; Tetsuya Shindo; Kohei Hashimoto; Fumimasa Fukuta; Ko Kobayashi; Taro Sugawara; Tadashi Hasegawa; Naoya Masumori
Journal:  Int Cancer Conf J       Date:  2020-07-24

2.  Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.

Authors:  Leonidas N Diamantopoulos; Ali Raza Khaki; Petros Grivas; John L Gore; George R Schade; Andrew C Hsieh; John K Lee; Todd Yezefski; Evan Y Yu; Michael T Schweizer; Heather H Cheng; Sarah P Psutka; Daniel W Lin; Maria S Tretiakova; Funda Vakar-Lopez; Robert B Montgomery; Jonathan L Wright
Journal:  Bladder Cancer       Date:  2020-03-28

3.  Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.

Authors:  Sumanta K Pal; Dean Bajorin; Nazli Dizman; Jean Hoffman-Censits; David I Quinn; Daniel P Petrylak; Matthew D Galsky; Ulka Vaishampayan; Ugo De Giorgi; Sumati Gupta; Howard A Burris; Harris S Soifer; Gary Li; Hao Wang; Carl L Dambkowski; Susan Moran; Siamak Daneshmand; Jonathan E Rosenberg
Journal:  Cancer       Date:  2020-03-24       Impact factor: 6.860

4.  Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.

Authors:  Gillian Vandekerkhove; Jean-Michel Lavoie; Matti Annala; Andrew J Murtha; Nora Sundahl; Simon Walz; Takeshi Sano; Sinja Taavitsainen; Elie Ritch; Ladan Fazli; Antonio Hurtado-Coll; Gang Wang; Matti Nykter; Peter C Black; Tilman Todenhöfer; Piet Ost; Ewan A Gibb; Kim N Chi; Bernhard J Eigl; Alexander W Wyatt
Journal:  Nat Commun       Date:  2021-01-08       Impact factor: 14.919

Review 5.  Reviving the Autopsy for Modern Cancer Evolution Research.

Authors:  Tamsin Joy Robb; Rexson Tse; Cherie Blenkiron
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

6.  A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.

Authors:  Elise Y Cai; Jose Garcia; Yuzhen Liu; Funda Vakar-Lopez; Sonali Arora; Holly M Nguyen; Bryce Lakely; Lisha Brown; Alicia Wong; Bruce Montgomery; John K Lee; Eva Corey; Jonathan L Wright; Andrew C Hsieh; Hung-Ming Lam
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

7.  Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma.

Authors:  Wei Ouyang; Lufeng Luo; Junjie Zhang; Ran Xu; Qiang Lu; Zhenzhou Xu; Jianye Liu; Pei Li; Yaqun Zhang; Chuanchi Zhou; Wei Tang; Zhenting Wang; Manman Cao; Genming Xu; Long Wang
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

8.  mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation.

Authors:  Sujata Jana; Rucha Deo; Rowan P Hough; Yuzhen Liu; Jessie L Horn; Jonathan L Wright; Hung-Ming Lam; Kevin R Webster; Gary G Chiang; Nahum Sonenberg; Andrew C Hsieh
Journal:  JCI Insight       Date:  2021-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.